News

Miami-One year into a 2-year study using an optical coherence tomography (OCT)-guided variable dosing regimen for ranibizumab (Lucentis, Genentech) for neovascular age-related macular degeneration (AMD), two key findings have emerged, according to lead investigator Philip Rosenfeld, MD, PhD.

New York-Patients undergoing surface ablation procedures performed using the Epi-K (Moria) for epithelial flap creation had better uncorrected visual acuity (UCVA) and comfort early on when the flap was replaced (epi-LASIK) than when it was removed (advanced surface treatment). However, surface ablation with flap removal may be associated with a benefit of better UCVA at 1 month, according to the results of a prospective clinical trial.

Rochester, NY-The incidence of postoperative astigmatism is significantly associated with the presence of preoperative coma, secondary astigmatism, and the discrepancy in preoperative astigmatism between wavefront and manifest subjective refractions, according to Manoj Subbaram, PhD.

Rochester, MN-"Bladeless" LASIK performed with a femtosecond laser was equivalent to LASIK performed with a microkeratome in a comparison study using a series of vision and eye health measurements.

Maastricht, The Netherlands-Preliminary results with the foldable iris-claw myopic phakic IOL (Artiflex, Ophtec) indicate it has a similar safety index when compared with the original polymethylmethacrylate (PMMA) model (Artisan, Ophtec), but is associated with less early induced refractive astigmatism, which results in a better efficacy index initially and shorter visual recovery curve, said Rudy M.M.A. Nuijts, MD, PhD.

Margate, FL-Eyes with mixed astigmatism have a range of naturally occurring higher-order aberrations that consist primarily of coma and spherical aberration. Wavefront-guided LASIK may be beneficial over conventional LASIK because of decreased higher-order aberrations overall, according to Raymond Gailitis, MD.

Stanford, CA-Wavefront-guided LASIK re-treatment procedures with the VISX CustomVue platform (VISX/Advanced Medical Optics [AMO]) seem to be effective, predictable, and safe in eyes with residual myopia using Fourier-based treatment software, reported Gloria Wang, MD.

New York-The latest upgrades to the Amadeus II microkeratome (Advanced Medical Optics) offer surgeons the flexibility to perform epi-LASIK and lamellar epithelial debridement as well as conventional LASIK without adding a new handpiece or control box. The only new components required are a small holder for the separator used in epi-LASIK as well as a new head, both of which are part of the package when the Amadeus II is purchased, according to Eric Donnenfeld, MD, FAAO, FACS, Ophthalmic Consultants of Long Island.

I have made two changes in my surgical technique to enhance outcomes with presbyopia-correcting IOLs.

Stanford, CA-Myopic patients who underwent CustomVue wavefront LASIK with the S4 laser (VISX, Advanced Medical Optics) with a Fourier-based program had better efficacy and predictability 1 year after the surgery than those with a Zernike-based system, according to Judy I. Ou, MD.

It was December 1980 and I was waiting for my first meeting with the esteemed corneal surgeon Richard Troutman, MD. I was in the middle of my first year of medical school and had just received an NIH summer training grant to use in a project of my choosing.

Since our practice began offering presbyopia-correcting IOLs, we have implanted 450 of them. One in five of our cataract and refractive lens exchange patients chooses one of these new lenses. The AcrySof ReSTOR lens (Alcon Laboratories) accounts for 80% of our presbyopia-correcting implants, while the ReZoom (Advanced Medical Optics) and the crystalens (eyeonics) together represent 20%.

Columbia, SC-The Light Touch technique of conductive keratoplasty (CK, Refractec), developed by refractive specialist Henry L. "Rick" Milne, MD, shows promise in the correction of near vision in patients with presbyopia, explained Dr. Milne.

Bogota, Colombia-Results from lengthening follow-up of patients who have undergone CustomVue (Advanced Medical Optics/VISX) peripheral excimer laser ablation indicate it is a safe and effective treatment for myopia and pure presbyopia. Also, initial results are encouraging regarding the benefit of iris registration for enhancing outcomes of wavefront-guided multifocal ablation to treat hyperopic presbyopia, said Gustavo E. Tamayo, MD.

New York-Several options can be offered to refractive surgery patients who are candidates for surface ablation procedures, and those individuals should be informed about differences between procedures with respect to speed of visual rehabilitation and postoperative comfort, said Gary R. Fishman, MD.

Rockville, MD-The Association for Vision and Ophthalmology (ARVO) has announced the next recipient of its Friedenwald Award and a new member of its supporting organization's governing board.

Vancouver, British Columbia-Peter Hnik, MD, MHS, has been named chief medical officer of iCo Therapeutics Inc. The biotechnology company is developing pre-existing drugs for a range of new conditions affecting isolated biologic environments-areas such as the eye, spinal cord, and joints, where locally administered application of these therapies would have minimal systemic distribution and fewer safety issues.

Santa Ana, CA-Mich?l Shuler has joined Advanced Medical Optics [AMO]/VISX as the new laser vision correction director of global strategic accounts. Primarily working with VISX technology, he will assist management with key accounts domestically and internationally.

In November 1976, President Gerald Ford and Vice-President Nelson Rockefeller likely "got down" to the popular new song, "Play That Funky Music" and viewed the top-grossing movie, Rocky. Mao Tse-Tung died, two amateur electronics enthusiasts developed the Apple computer in a California garage, USC beat Michigan in the Rose Bowl, the Celtics swept Phoenix in the NBA finals, and Cincinnati prevailed over the Yankees in the World Series. The cost of a home averaged $48,000, a gallon of gas was 59 cents, the Dow's high for the year was 1,004, yours truly was a college sophomore, and Ophthalmology Times mailed its first issue.

Bescia, Italy-A patient questionnaire about their experience with refractive surgery is in the process of development by the Italian Refractive Surgery Society. The preliminary results reported by Elena Scaffidi, Psych MA, indicate that the questionnaire was well perceived by patients and provided a great deal of input for improving their experience.

Lexington, KY-Animal studies point to two components of drusen as the driving force for the neovascularization that causes age-related macular degeneration (AMD) -a discovery that opens the way to early detection and drug therapy to prevent the condition, said Jayakrishna Ambati, MD.

Waltham, MA-OxiGENE Inc., a clinical-stage biopharmaceutical company developing novel therapies to treat eye diseases and cancer, is now focusing its ophthalmology strategy on oral or other non-intravitreal forms of administration of Combretastatin A4 Phosphate (CA4P) for age-related macular degeneration.

Boston-Global bio-nanotech company pSivida Ltd. has begun a phase II clinical trial of the steroid receptor antagonist mifepristone (RU486) as an eye-drop treatment for steroid-associated elevated IOP. The investigator-sponsored trial is expected to involve up to 45 patients in the United States.

Santa Clara, CA-OptiMedica Corp. has received ISO 13485 certification, and the Pascal photocoagulator has received CE Mark approval and is now available for sale internationally.

Below is a partial list of the contributions made by researchers at the Jules Stein Eye Institute and the University of California, Los Angeles, over the past 40 years.

Los Angeles-As the Jules Stein Eye Institute (JSEI) celebrates 40 years of contributions to research, education, and patient care this month, construction is approaching for a major new building that will help carry the institution into future decades.

Exhibit Hall Highlights

Bayer Healthcare and Regeneron Pharmaceuticals Inc. have agreed to collaborate on the development of the vascular endothelial growth factor (VEGF) Trap through a global plan that encompasses the neovascular form of age-related macular degeneration (AMD), diabetic eye diseases, and other eye diseases and disorders. The companies jointly will commercialize the VEGF Trap-Eye outside the United States and will share equally in profits from ex-U.S. sales. Within the United States, Regeneron has exclusive commercialization rights in all indications and will retain 100% of profits from any such sales.

eyeonics, manufacturer of crystalens, placed 45th in technology for Deloitte’s prestigious Technology Fast 500. The list ranks the top technology, media, telecommunications, and life sciences companies in North America, based on the percentage revenue growth from 2001 to 2005. The company experienced 5,596% revenue growth during that time.

PBA accepting